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A single promoter has so far been found in the long control region (LCRs) of human papillomavirus-16 (HPV-16). Multiple
promoters exist in the LCRs of several other papillomaviruses, which are spliced to become mRNAs for late and some early
genes. Here we have investigated whether such promoters exist in the LCR of HPV-16. In in vitro transcription experiments,
we detected a strong transcript starting 280 bp downstream from the 3 end of the L1 gene between a nuclear matrix
attachment region and the epithelial-specific enhancer. Promoter activity coincides with a GCCATTTT motif, which binds the
transcription factor YY1 (YY1-7436). The A of this motif is the first nucleotide of the transcripts and identifies YY1-7436 as an
initiator. Genomic segments with YY1-7436 initiate expression of a luciferase reporter gene in transfection experiments.
Mutational analysis of YY1-7436 suggests, however, that promoter function originates from another factor but YY1, which can
contact overlapping sequences. Promoter activity of YY1-7436 is modulated by upstream A-T-rich sequences, which bind the
basal transcription factor TFIID, and it is stimulated by the viral E2 protein binding to a downstream E2 binding site. In
differentiating W12 cells, which contain episomal HPV-16 copies, we detected transcripts including LCR sequences down-
stream of YY1-7436, which were differentially spliced to early and late genes. However, we could not detect 5 ends mapping
to YY1-7436, but we detected two novel HPV-16 promoters within the L1 gene. Conservation of the arrangement of the YY1
and E2 binding sites suggests a role in important biological functions, which, however, is difficult to confirm in every type ofupstream of the LCR. © 2003 Elsevier Science (USA)
INTRODUCTION
Genital human papillomaviruses (HPVs) are a phyloge-
netic group of about 40 HPV types that includes HPV-16, the
most common virus causing cervical carcinomas (IARC,
1995). Gene expression and replication of these viruses
undergo complex regulatory processes during epithelial
differentiation, early and late phases of the viral life cycle,
and changes of the host cell and the viral genome in tumor
progression. Most of the cis-responsive elements that in-
fluence viral transcription and replication are located in the
long control region (LCR), an 850-bp genomic segment in
HPV-16, about 11% of the whole genome, and of similar size
in all other genital HPVs.
We are carrying out a systematic dissection of the cis-
responsive elements that regulate the HPV-16 life cycle.
The comparison of the LCRs of HPV-16 and other genital
HPVs point to similar organizations (O’Connor et al., 1995).
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All rights reseThe 3 portion, with a length of about 150 bp, contains the
replication origin and the E6 promoter, which has one
binding site for the transcription factor Sp1, two for the viral
factor E2, and a TATA box (Tan et al., 1994). The central
portion, with a size of about 400 bp, is bracketed by two
additional E2 binding sites, 140 and 550 bp 5 of the E6
promoter. It contains the epithelial-specific enhancer with
binding sites for numerous transcriptional activators and
repressors (Cripe et al., 1987; Gloss et al., 1987; O’Connor et
al., 1995, 1998). This enhancer, the E6 promoter, and the
replication origin are flanked by two nuclear matrix attach-
ment regions (MARs), one located in the 300-bp-long 5
region of the LCR and the other one in the E6 gene itself
(Tan et al., 1998; Stu¨nkel, 2000).
Only one promoter has so far been detected in the
LCR of HPV-16, the E6 promoter P97 (Tan et al., 1994). In
addition, HPV-16 has a differentiation dependent pro-
moter within the E7 gene (Grassmann et al., 1996), likely
homologous to one in a similar position of the closely
related type HPV-31 (Ozbun and Meyers, 1997). In the
LCR of HPV-31, four additional promoters have been
detected, including a constitutively active promoter at
position 7375 (Ozbun and Meyers, 1999). Four remotecell culture. The study of W12 cells complements the ex
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HPV-8, have one or several promoters in addition to the
one that initiates transcription of E6. The 5 portion of the
LCRs of each of these viruses contains a promoter that
gives rise to transcripts of late genes (Baker and Howley,
1987; Haller et al., 1995; Stubenrauch et al., 1996;
Wettstein et al., 1987). No homologues of these promot-
ers are known from genital HPVs. In BPV-1, there is yet
another promoter in the 5 LCR, whose regulation by the
E2 protein and cellular factors has been studied, but
whose function is not yet understood (Stenlund et al.,
1987; Vande Pol and Howley, 1990). Here we report the
detection of a promoter in the 5 portion of the LCR and
two additional ones in the L1 gene.
The LCRs of genital HPV types have diversified so
much during evolution that it is impossible to align the
LCRs of unrelated HPVs. Short conserved segments,
however, point to functional importance as a result of
selection against mutational changes. The transcripts
that we report start from such a conserved segment, a
stretch of 30 nucleotides between the MAR in the 5 part
of the LCR and the epithelial-specific enhancer. This
segment contains the motif GCCATTTT, known to be
bound by the YY1 factor, and the motif ACCGN4CGGT, a
binding site of the papillomavirus transcription factor E2.
It has been reported that the YY1 site of HPV-16 does not
silence the enhancer, in contrast to several YY1 sites
further downstream (O’Connor et al., 1996), while the
corresponding YY1 site of HPV-31 positively influences
the E6 promoter (Kanaya et al., 1997). The E2 site weakly
stimulates the E6 promoter, which is 550 bp to the 3 site
(Dollard et al., 1993; Steger and Corbach, 1997).
YY1 sites are most often repressors of transcription
(Hahn, 1992; for its role in HPV-16 transcription see May
et al., 1994; O’Connor et al., 1996), although it can also act
as a transcriptional activator (Maldonado et al., 1996). In
addition, it can also bind an initiator, a promoter element
that overlaps with the transcription start and comple-
ments a TATA box or even functions without it, as re-
ported for the P5 promoter of the adenoassociated virus
(AAV-P5) (Seto et al., 1991) and the promoter of cyto-
chrome c oxidase (Basu et al., 1993). In AAV-P5, YY1
binds overlapping with the transcriptional start site and
stimulates transcription through initiation at the A and
the first T of the GCCATTTT motif. In in vitro transcription
experiments, this promoter is dependent only on YY1,
TFIIB, and RNA polymerase II and independent of TFIID
(Houbaviy et al., 1996; Zenzie-Gregory et al., 1992).
AAV-P5 is only one example of an initiator (Kraus et al.,
1996; Smale, 1997; Smale and Baltimore, 1989). Other
initiators have nucleotide sequences diverging from YY1
binding sites and bind YY1 bind only weakly or not at all.
Some of these initiators are activated by the TAF150 and
TAF250 subunits of TFIID, others by the RNA polymerase
II, and yet others by the transcription factors USF1 and
TFII-I (Javahery et al., 1994; Kaufmann and Smale, 1994;
Kaufmann et al., 1996; Purnell and Gilmour, 1993; Roy et
al., 1997, 1991; Weis and Reinberg, 1997). In some TATA-
less promoters with functional initiators the binding of
TFIID is sufficiently mediated by TAF150 and TAF250 and
TBP is dispensable for this activity (Chalkley and Verrijzer,
1999; Martinez et al., 1994; Verrijzer et al., 1995; Wieczorek
et al., 1998). In other promoters, TBP mediates the binding
of TFIID, albeit through a degenerate TATA box (Bogomol-
ski-Yahalom et al., 1997). This may suggest that there are
multiple mechanisms for the activity of initiators (Veenstra
andWolffe, 2001). Here we report the analysis of a promoter
in the 5 LCR of HPV-16, which binds YY1 overlapping to the
initiator element, but which functions apparently depending
on other factors, including TFIID.
RESULTS
In vitro transcription experiments identify a promoter
in the 5 part of the HPV-16 LCR, which overlaps with
a YY1 binding site
To examine whether the 5 part of the HPV-16 LCR
contains a promoter, we cloned into the vector pGL3b
genomic fragments corresponding to this part of the
LCR. These extended from two 5 positions within the L1
gene and from several positions within the 5 part of the
LCR to the positions 7471 or 7469, respectively (Fig. 1B).
These 3 ends are close to and downstream of a con-
served E2 binding site around position 7460 and 50 bp
upstream of the epithelial specific enhancer. We exam-
ined these vectors in in vitro transcription experiments
with HeLa nuclear extracts and searched for transcripts
by primer extension with a primer complementary to the
luciferase open reading frame in the pGL3b vector.
Figure 1A, slot 1, shows a double band generated by
the largest construct, pGL3b1320, which contains the 5
LCR and part of the L1 gene. These 99-nucleotide-long
primer extension products identify transcripts whose 5
ends coincide with the center of the sequence GC-
CATTTT of HPV-16, a YY1 binding site that we had de-
scribed previously (O’Connor et al., 1996), which we refer
to as YY1-7436. The same start was observed with all
deletion derivatives. A difference in the construction of
these six clones produces a double band migrating 6
and 7 nucleotides more slowly than those generated by
pGL3b1320, which corresponds to the same 5 end po-
sition (Fig. 3, slots 2 to 7). The sizes of these bands
identify a 5 end within the YY1-7436 motif. The shortest
segment present in pGL3b40 shows stronger transcrip-
tion than all other clones, suggesting that sequences
upstream of YY1-7436 may repress initiator function. Slot
8 shows the analysis of pGL3b703 with natural HPV-16
enhancer sequences instead of the chimeric luciferase
gene downstream of YY1-7436. In this experiment, we
used a primer corresponding to HPV-16 sequences, and
the resulting reaction products with a length of 115 nu-
cleotides correspond to a start at YY1-7436. As a nega-
tive control, no transcript could be observed with the
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insert-free vector pGL3b (slot 9). As a control for the
strength of YY1-7436 activity, we included a vector with
the early promoter of SV40. Slot 10 shows similar but
slightly higher activity of this control vector. We conclude
that in vitro experiments identify a single, well-defined,
and strong promoter in the 5 part of the HPV-16 LCR.
Figure 1C shows a comparison of the initiator function
of YY1-7436 with that of the TdT initiator, one of the
paradigms for initiator research (Smale, 1997). As can be
seen, both elements induced transcripts whose 5 ends
mapped to the A and the first T of the CATT consensus
of the GCCATTTT and CTCATTCT motifs, respectively,
the signals being of similar strength in the context of the
enhancer-free pGL3b vector. These findings suggest
functional similarity of the two initiator sequences, al-
though the HPV-16 initiator is a binding site for the YY1
factor, while the TdT initiator has little affinity for YY1.
Conservation of a YY1 consensus motif and an E2
binding site in genital HPVs
Toward a detailed analysis of YY1-7436, we investi-
gated the genomic sequences surrounding this site. The
top part of Fig. 2 shows the organization of functional
FIG. 1. (A) In vitro transcription of genomic segments of the 5 part of the LCR of HPV-16 identifies a single start site overlapping a GCCATTTT YY1
binding motif (YY1-7436). Two transcripts with lengths of approximately 99 nucleotides (slot 1) were generated from the largest construct, pGL3b1320,
which contains the 5 LCR and part of the L1 gene upstream of YY1-7436 and extends to position 7471. The 5 end of this transcript corresponds to
the A and the 5 most T of this YY1 motif. The same start was observed with all deletion derivatives (slots 2 to 7); the two bands migrated six and
seven nucleotides more slowly than those generated by pGL3b1320, as expected from a difference in these constructs. The same start was observed
when natural HPV-16 sequences replaced the luciferase gene downstream of position 7471 (pGL3b703, slot 8), and no transcript was generated by
the insert-free vector pGL3b (slot 9). An enhancer-free vector containing the early promoter of SV40 (slot 10) shows similar but slightly higher activity
in comparison to HPV-16 YY1-7436. Four slots on the left side of the panel identify the sequence of HPV-16 aligned precisely against the homologous
sequence in pGL3b1320. Slot 11 is a control without a nuclear extract to ensure that the activity is not due to residual DNA left after DNase I digestion.
(B) Schematic representation of the genomic segments of HPV-16 straddling YY1-7436. (C) Transcripts generated by HPV-16 YY1-7436 (slot 1) do not
differ qualitatively or quantitatively from transcripts generated by the YY1-independent initiator TdT initiator (slot 2), even in the presence of the A-T-rich
sequence of HPV-16 23 bp upstream of YY1-7436 (slot 3). These in vitro transcripts were generated by cloning the oligos HPV-16 YY1-7436 and TdT
Inr into pSP72 and processing the transcripts with a primer complimentary to vector sequences.
488 TAN ET AL.
elements and protein binding sites of the LCR of HPV-16.
The bottom part of Fig. 2 shows a segment of 30 bp
positioned between the 5 part of the LCR and the central
part with the epithelial specific enhancer. In 18 genital
HPV types, this segment contains a highly conserved
YY1 motif and an E2 binding site. In some groups of
genital HPVs, such as HPV-2 and HPV-27, and HPV-6 and
HPV-11, the YY1 motif is missing. In HPV-16, but not in
most of the other HPV types, an A-T-rich stretch to the 5
side of the YY1 site is reminiscent of a sequence aber-
rant TATA box. In most other genital HPVs there is a
second YY1 site in this position, continuing into an A-T-
rich stretch farther upstream (Myers et al., 1995).
The YY1 consensus motif of HPV-16 binds the YY1
factor
YY1-7436 is 1 of 10 YY1 sites within the LCR of HPV-16,
the only site outside the enhancer–promoter segment
and not involved in transcriptional repression (O’Connor
et al., 1996). Here we confirmed in bandshift experiments
with recombinant YY1 expressed in Escherichia coli (Fig.
3A) and with nuclear extracts from HeLa cells (Fig. 3B)
that YY1-7436 strongly binds the YY1 factor, just like the
homologous site of HPV-18 (HPV-18-7442). These two
bandshifts migrate identically to those representing YY1
sites from the AAV-P5 initiator (Seto et al., 1991) and two
YY1 sites involved in transcriptional repression, namely,
from an upstream YY1 site of the AAV-P5 promoter (AAV-
P5-60) (Shi et al., 1991) and from the human immunoglob-
ulin  enhancer 3 (HuE3) (Park and Atchison, 1991). As
published, no bandshift was observed with an oligo
representing the TdT initiator, which has some sequence
similarity to the other sites and functions as an initiator,
just like AAV-P5. Supershift and crosswise competition
experiments confirm the identities of the HPV-16 YY1-
7436 complex (Fig. 3C). Figures 3D and 3E show a
FIG. 2. A 35-bp segment in the LCR of HPV-16 with binding sites for YY1 and E2 that is conserved among most genital HPV types. The top part
of the figure shows the end of the L1 gene and the start of E6, which flank the LCR. Arrows identify a previously described transcription termination
and polyadenylation site (pA), the epithelial-specific enhancer, the silencer, the replication origin (ori), and the E6 promoter. Transcription factor
binding sites are shown by the symbols YY1, E2, NFI (nuclear factor 1), AP1 (activator protein 1), GR/PR (glucocorticoid and progesteron receptor),
TF1 (transcription enhancer factor 1), TF2 (transcription enhancer factor 2), oct (octamer binding factor-1), E1 (replication factor E1), and PSM
(papillomavirus silencing motif). The bottom part of the figure shows the alignment of apparently homologous segments from the LCRs of various
genital HPV types, located between the respective MARs and the enhancers. The HPV genome sequences of 18 HPV types were aligned using the
Clustal algorithm from the MEGALIGN module of DNASTAR software (DNASTAR Inc., Madison, Wisconsin). The consensus sequence resulting from
this alignment is shown together with bars, which quantify the amount of consensus. YY1 and E2 binding sites are indicated below the alignments,
as well as the extension of this conserved segment to the 5 side in case of HPV-16.
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mutational comparison of the AAV-P5 and the HPV-16
YY1-7436 sites and the TdT initiator using for the band-
shift either a recombinant YY1 expressed in E. coli (Fig.
3D) or a nuclear extract (Fig. 3E). For the exact nature of
the mutants, see Table 1. As in Figs. 3A and 3B, strong
YY1 bandshifts are seen with the AAV-P5 and the HPV-16
FIG. 3. The HPV-16 motif YY1-7436 binds the YY1 factor in a manner similar to that of known YY1 sites with initiator or repressor function and
differing from the TdT initiator with low affinity for YY1. A and D show bandshift experiments with recombinant YY1 factor expressed in Escherichia
coli and B, C, and E with nuclear extracts from HeLa cells. Oligonucleotides representing AAV P5, AAV P5-60, the human immunoglobulin  enhancer
3 (HuE3) YY1 site, terminal deoxynucleotide transferase initiator (TdT Inr), HPV-16 YY1-7436, and HPV-18 YY1-7442 are listed in Table 1A. The two
HPV oligos give typical YY1 bandshifts similar to the oligos of AAV P5, AAV P5-60, and HuE3, while the TdT Inr sequence shows little or no binding.
The identity of the HPV-16 YY1-7436 shift is confirmed by supershift and competition experiments (C, slots 2 and 3 to 6); D (E. coli expressed YY1)
and E (nuclear extracts show a mutational comparison of the AAV-P5 and the HPV-16 YY1-7436 sites and the TdT Inr as described in detail under
Results.
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YY1-7436 oligonucleotides (slot 1 and 5). Deviating from
Figs. 3A and 3B, but in accordance with published data
(Javahery et al., 1994), the TdT initiator oligo shows weak
binding of YY1, despite the very high activity of YY1 in
these two distinct preparations (slot 3).
Binding of YY1 to YY1-7436 is eliminated by mutating
TABLE 1
Oligonucleotides Used in This Study
A
1. AAV P5 GGTCTCCATTTTGAAGCG
2. AAV P5m GGTCTaaATTTTGAAGCG
3. TdT Inr AGCCCTCATTCTGGAGAC
4. TdT Inr m AGCCCTCATcgaGGAGAC
5. AAV P5-60 YY1 TTGCGACATTTTGCGACA
6. Human kE3 YY1 CACCTCCATCTTGTTTGA
7. HPV-18 YY1 7442 ATCCTCCATTTTGCTGTG
8. HPV-16 YY1 7436 AGCGGCCATTTTGTAGCT
9. HPV-16 YY1 7436m0 AGCGGCtgcTTTGTAGCT
10. HPV-16 YY1 7436m1 AGCGGCaATTTTGTAGCT
11. HPV-16 YY1 7436m2 AtgaGatATTTTGTGACT
12. HPV-16 YY1 7436m3 AGCGGCCAacTTGTAGCT
13. HPV-16 YY1 7436m4 AGCGGaaATTTTGTAGCT
14. HPV-16 YY1 7436m5 AGCGGCCATcgaGTAGCT
15. HPV-16 YY1 7436m6 AGCGGaaATcgaGTAGCT
16. p97TATA GATTCCCGGTTAGTATAAAAGCAGAA
17. 7406TA AGCTTATATATACTATATTTTGTAGG
18. 7406TAm1 AGCTTATATATACTAgcgTTTGTAGG
19. 7406TAm2 AGCTTAcggcTACTATATTTTGTAGG
20. 7406TAm3 AGCTTAcggcTACTAgcgTTTGTAGG
21. TA-YY1 7436 (17) ACTATATTTTGTAGCGCCAGCGGCCATTTTGTAGCT
22. pGL3b(e)40 CCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCAT
23. pGL3b(e)58 ATACTATATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCAT
24. pGL3b(e)65 TTTATATATACTATATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCAT
B
Oligo HPV-16 nt position Description Size (mer) Sequence
59 Linker LP 23 CAACGGCATGGATAACAGCAGGG
62 Long UP 39 GCGGAATCGACTCACTATAGGGCAACGGCATGGATAACA
63 Short UP 22 GCGGAATCGACTCACTATAGGG
64 Nested UP 19 CAACGGCATGGATAACAGC
65 7602-7581 AS 22 ATGGAATGGTTGGCAAGCAGTG
66 7683-7659 AS 25 CGTTGGCGCATAGTGATTTATTTTA
67 7706-7685 AS 22 GTGCCTAACAGCGGTATGTAAG
68 7782-7758 Outer AS 25 GACATTTAGTTGGCCTTAGAAGTTT
oCCB-181 7456-7477 Outer S 22 GAATTCGGTTGCATGCTTTTTG
oCCB-182 7475-7497 Inner S 23 TTGGCACAAAATGTGTTTTTTTA
oCCB-183 3597-3575 Outer AS early 23 CAGTTAATCCGTCCTTTGTGTGA
oCCB-184 5931-5909 Outer AS late 23 AGCCGCTGTGTATCTGGATTATA
oCCB-187 3474-3457 Inner AS early 18 CGCTGGATAGTCGTCTGT
oCCB-188 5711-5691 Inner AS late 21 CCGTGCTTACAACCTTAGATA
oCCB-189 7439-7458 Outer S 20 ATTTTGTAGCTTCAACCGAA
oCCB-312 7455-7474 S 20 CGAATTCGGTTGCATGCTTT
oCCB-313 7525-7506 AS 20 AAACCATAGTTGCTGACATA
Note. (1A) AAV P5, which represents a YY1 binding site with initiator function, and the mutant AAV-P5m have been designed following a published
mutant. The oligos TdT Inr (for initiator) and its mutant TdT Inr m were derived from a study by Javahery et al. (1994) and represent an initiator element
with little or no affinity for YY1. AAV P5-60 YY1 and human kE3 YY1 represent published YY1 sites with repressor function. HPV-18 YY1-7442 is a YY1
binding motif in a position homologous to that of HPV-16 YY1-7436. The oligos HPV-16 YY1-7436m0 to m6 were designed by us, m3 and m5 mimicking
the mutations of AAV-P5m and TdT Inr m. The oligo P97TATA includes the well-researched TATA box of the HPV-16 P97 promoter, a positive control
for the binding of factors to 7406TA, which included the A-T-rich element upstream of YY1-7436. The first T of this oligo is identical to the genomic
position 7406 of HPV-16. The mutants 7406m1 to m3 alter the proximal, the distal, and both potential TATA boxes. The oligo TA-YY1-7436(17)
represents the sequence used to identify the initiator start site in Fig. 1C, lane 3. The oligos pGL3b40, pGL3b58, pGL3b65, pGL3e40, pGL3e58, and
pGL3e65 were used to construct the vectors, which were named accordingly. (1B) Oligos used in RT–PCR experiments: LP, linker primer; UP, upper
primer; S, sense strand; AS, antisense strand; inner or outer refers to the order in nested PCR experiments; early or late indicates location of the primer
in the HPV genome.
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the GCCATTTT motif to GAAATTTT (mutant m4, slot 10).
This mutation was modeled following a published muta-
tion of AAV-P5 (CCATTTT to AAATTTT, ref. 54) (slot 2) and
behaved in our hands as published (AAV-P5m, slot 2).
YY1 is not affected by mutation of the HPV-16 site to
GCCATCGA (mutant m6, slot 11), which eliminates the
function of the TdT initiator (Javahery et al., 1994). When
present in the TdT initiator oligo, the same mutation only
weakly affects the binding of YY1 and the slow migrating
complex (slot 4). Slots 6 to 9 and 12 show bandshifts of
additional YY1 mutants. Four of these five mutants (mo,
m1, m2, and m6) eliminate YY1 binding, while one (GC-
CAACTT, mutant m3 in slot 9) affects it only slightly. It can
be learned from these mutations that the three thymidine
residues at the 3 end of the YY1 motif are dispensable
for high-affinity YY1 binding, with the strongest contribu-
tions coming from the CCAT motif.
Mutational comparison of the initiator function of
HPV-16-YY1-7436, AAV-P5-YY1, and the TdT initiator
To examine the initiator function of the mutations that
we had studied for YY1 binding, we cloned oligos con-
taining these mutant nucleotide sequences into the vec-
tor pIII and studied these clones in in vitro transcription
experiments. Figure 4 shows that the published mutants
of AAV-P5 and the TdT initiator behaved as expected.
AAV-P5 showed strong initiator function, while AAV-P5m
completely lost this function correlating with the elimina-
tion of YY1 binding. Also in accordance with published
data, the TdT element behaved as a strong initiator,
although it bound YY1 very weakly, and lost most of its
activity when it was mutated. The HPV-16 mutant YY1-
7436m4, modeled according to AAV-P5m, behaved just
like this mutant and concomitantly lost initiator function
and YY1 binding. In a similar manner, the mutants YY1-
7436m0, m1, m2, and m6, which we had designed,
showed reduced initiator function and loss of YY1 bind-
ing. These correlations of YY1 binding and initiator func-
tion contrasted with the behavior of YY1-7436m5 and m3.
YY1-7436m5, modeled according to the TdT initiator mu-
tation by change of the YY1 binding site GCCATTTT to
GCCATcga, had very low transcriptional activity, although
having a strong affinity for YY1. The same applies to
YY1-7436m3, with the sequence GCCAacTT. In summary,
YY1 binding as well as initiator function is affected by
mutations altering the first four bases of the GCCATTTT
motif, while mutations eliminating initiator function but
not YY1 binding had changes in the four thymidine res-
idues.
HPV-16 YY1-7436 functions as an initiator in vivo
To study whether YY1-7436 functions as an initiator in
vivo, we transferred the HPV-16 sequences flanking YY1-
7436 that were examined in vitro into the vector pGL3e.
This vector contains the SV40 enhancer and was chosen
because similar constructs in the enhancer-free pGL3b
gave only very weak luciferase signals. Figure 5 shows
luciferase activity induced by these constructs trans-
fected into HeLa cells. pGL3e40, the clone with the
shortest segment encoding YY1-7436 and the down-
FIG. 4. Mutations affecting the GCCATTTT motif or surrounding nucleotides (see Table 1A) reduce or eliminate the initiator function of YY1-7436.
Slots 1 and 3 show the initiator function of the TdT initiator and of AAV-P5, and slots 2 and 4 lack of initiator function by clones modeled according
to published mutations (23, 40). The initiator function of HPV-16 YY1-7436 (slot 5) is negatively affected by a variety of mutations throughout the
GCCATTTT motif, in particular in the case of m4 and m5, which mimic the TdT initiator and the AAV-P5 mutations. Note that the loss-of-initiator-function
mutants m3 and m5 had not affected YY1 binding (Fig. 3). Controls show a lack of activity of the initiator-free vector pIII (slot 13), in the absence of
nuclear extract (slot 14), and, in the presence of nuclear extract, with RNA polymerase II activity inhibited by -amanitin (final concentration, 2 mg/ml)
(slot 15).
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stream E2 site, stimulates luciferase expression about
10-fold over the promoterless vector pGL3e and reaches
about 10% of the activity of the positive control, pGL3e
with the SV40 enhancer and promoter (pGL3e-control).
Inclusion of an additional 18 bp on the 5 side of YY1-
7436 results in a slight repression (pGL3e58), while an
additional 7 or 44 bp (pGL3e65 and pGL3e102) stimu-
lates transcription. This may indicate that the A-T-rich
sequence 23 bp upstream of YY1-7436, present in
pGL3e58, does not function as a TATA box, while the
A-T-rich sequence 32 bp upstream in pGL3e65 and
pGL3e102 may do so. HPV-16 sequences further up-
stream repress transcription (pGL3e217, 321, 651, and
1320), possibly a consequence of the MAR.
The TATA box binding protein (TBP) binds the A-T-rich
segment upstream of YY1-7436
Two A-T-rich sequences, TATATATA and TATATTTT, ex-
ist 32 and 23 bp upstream of YY1-7436. As some initiators
function in the context of a TATA box, which is located
about 32 bp upstream of the first transcribed nucleotide,
we investigated whether these sequences can bind the
basic transcription factor TFIID or its subunit TBP, re-
spectively. Figure 6A shows a bandshift of an oligonu-
cleotide with both of these two A-T-rich sequences
(7406TA, Table 1) with nuclear extracts of HeLa cells and
migration of this shift identically to one generated by an
oligonucleotide with the HPV-16 P97 TATA box. The mu-
tant 7406TAm1 has a mutation in the A-T-rich sequence
close to YY1-7436, leading to a slight reduction of the
shifted band, while 7406TAm2 in the distal A-T-rich se-
quences is strongly reduced. The double mutant
7406TAm3 does not lead to the establishment of any
protein–DNA complex. We conclude from this that the
proximal A-T-rich sequence has a low and the distal a
strong affinity to a TBP containing complex (Ge and
Roeder, 1994). This conclusion is further corroborated by
gel shift competitions (Fig. 6A, slots 6 to 10), a supershift
with anti-TBP antiserum (Fig. 6B), and a shift of these
oligos with bacterially expressed TBP (Fig. 6C). In Fig.
6B, the addition of anti-TBP antiserum before and after
addition of nuclear extracts in lanes 3 and 5, respectively,
blocked the binding of a TBP containing complex (top
band).
The downstream E2 binding site E2-7453 stimulates
the function of YY1-7436
The HPV transcription factor E2 binds about 10 bp
downstream of YY1-7436, and this site and the distance
between the YY1 and E2 sites are conserved among
most genital HPVs. To investigate whether E2 influences
the function of YY1-7436, we contransfected pGL3e40,
pGL3e102, and the E2 site mutant pGL3e102(E2m) and
the HPV-16 E2 expression vector pXJ41-E2 into HeLa
cells. Figure 7A shows that E2 can activate the initiator
function of YY1-7436 by a factor of 2 to 3 in pGL3e40 and
pGL3e102. This induction is dependent on the E2 site, as
shown by its mutation pGL3d102(E2m). A double band-
shift (Fig. 7B) shows that E2 and YY1 both bind this
sequence directly or by mutual contact. We conclude
from these observations that E2 stimulates the initiator
function of YY1-7436, although its binding site is posi-
tioned immediately downstream of this and may lead to
topological interference between E2 and the elongating
RNA polymerase II, as in the case of the late promoter of
HPV-8 (Stubenrauch et al., 1996) and the promoter p7185
of BPV-1 (Stenlund and Botchan, 1990).
Characterization of transcripts including LCR
sequences
So far, no transcripts have been reported that include
sequences of the HPV-16 LCR. In order to search for
such transcripts, which might originate from YY1-7436,
we isolated total RNA from 20863 cells, derivatives of
W12 cells (Jeon et al., 1995), which contain episomal
copies of the HPV-16 genome. These cells were grown
confluently for 10 days to induce differentiation, since in
our hands they did not differentiate well in raft cultures.
Spliced transcripts were detected by nested RT–PCR
using sense primers just downstream of YY1-7436 and
antisense primers in the 3 part of either the early or the
late region. Four mRNAs were detected that included
FIG. 5. In transfection and luciferase expression experiments in
HeLa cells, YY1-7436 functions as an initiator when present on short
genomic segments, while this function is repressed by the inclusion of
upstream sequences. pGL3e40 stimulates luciferase expression about
10-fold over the promoterless vector pGL3e and reaches about 10% of
the activity of pGL3e carrying the SV40 enhancer and promoter (pGL3e
control). Inclusion of an additional 18, 25, and 67 bp on the 5 side of
YY1-7436 results in a slight repression (pGL3e58) or stimulation
(pGL3e65 and pGL3e102, respectively) of transcription. HPV-16 se-
quences farther upstream repress transcription in vivo (pGL3e217, 321,
651, and 1320).
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sequences of the LCR downstream of YY1-7436. Two of
these contained downstream splices within early genes,
namely (7456)-880^3358-(3475) and (7456)-226^409-
880^3358-(3475), and two splices into late genes, namely
(7475)-226^409-880^5639-(5712) and (7475)-880^5659-
(5712) (“^” refers to a splice junction between two exons
and the numbers in parentheses refer to the ends of
RT–PCR products which are defined by the primers).
To enquire whether the 5 ends of these mRNAs might
be derived from YY1-7436, we performed 5-RACE exper-
FIG. 7. The HPV-16 transcription factor E2 stimulates the initiator function of YY1-7436 by binding concomitantly with YY1 to flanking binding sites.
(A) HeLa cells were contransfected with pGL3e40, pGL3e102, or the E2 site mutant pGL3e102(E2m), respectively, and with the HPV-16 E2 expression
vector pXJ41-E2 for determination of luciferase activity. (B) A slow migrating complex reveals a bandshift originating from YY1 and E2 to an oligo with
the YY1-7436 and the E2 binding site, either by concomitant DNA contact or by protein–protein interaction. The similarity in the bandshift positions,
in spite of the higher molecular weight of YY1, likely originates from the GST ends of the bacterially expressed E2 protein. The amounts of recombinant
E2 protein were, from lanes 2 to 9, 0.25, 0.5, 1, 2, 10, 50, 100, and 100 ng. Note that a bandshift generated by YY1 (slot 1) migrates at nearly the same
position as that derived from the binding of E2 (slot 9).
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iments with RNA samples from trichostatin A (TSA)-
treated 20863 cells. TSA is an inhibitor of histone
deacetylases and induces promoters which might be
silent due to repressive chromatin. These samples were
reverse transcribed with random hexamers (R) or HPV-
16-specific primers (Q) downstream from the putative
initiator site. A universal linker primer was attached to
the 3 end of full-length first strand cDNAs during reverse
transcription using a template switching technique
(Chenchik et al., 1998). Among 30 DNA fragments ampli-
fied by nested PCR, 13 clones were derived from HPV-16
mRNAs. All sequences contained the template switching
linker primer that was used in the RT reaction, indicating
that the 5 ends of these cDNAs correspond to the 5
ends of the mRNAs from which they were derived. Sur-
prisingly, none of these clones started at YY1-7436, but
rather had 5 ends in the L1 gene, 5 starting at position
6592 and 8 at position 7057 and 7058, suggesting two
likely novel promoters upstream of the LCR.
Taken together these results confirm that LCR se-
quences can be transcribed and processed into mRNAs
encoding HPV-16 genes. In addition, the 5-RACE results
identify two novel promoters in the L1 ORF with tran-
scriptional start sites at nts 6592 and 7057–7058. How-
ever, under the expression conditions that we could
establish in vivo, the YY1 initiator is not active at a level
sufficient to make its products detectable.
DISCUSSION
YY1-7436 identifies a transcriptional initiator that
binds YY1 but can function independently of this
factor
A YY1 site overlapping the initiator of the AAV-P5
promoter has become the paradigm for the capability of
YY1 to direct transcription initiation independently of the
TBP factor and of a TATA box (Houbaviy et al., 1996;
Hyde-DeRuyscher et al., 1995; Seto et al., 1991; Usheva
and Shenk, 1996), since for activation of this promoter in
vitro, YY1 requires only TFIIB and RNA polymerase II. It is
not clear, however, whether this reaction is TBP indepen-
dent in vivo. The properties of several transcriptional
initiators other than AAV-P5 have been extensively stud-
ied (for reviews see Kraus et al., 1996; Smale, 1997;
Veenstra and Wolffe, 2001; Wassarman and Sauer, 2001)
and suggest that many other initiator elements function
independently of YY1. The initiator function of some of
these promoters, such as the adenovirus major late
(AdML) promoter, depends on the cooperation of two
other initiator binding factors, TFII-I and USF1 (Du et al.,
1993; Roy et al., 1997, 1991; Wu and Patterson, 1999)
basic helix-loop-helix factors with specific DNA binding
sites. In yet other promoters, particularly well studied for
the TdT gene, contact to the initiator element seems to
depend on TFIID, but is apparently not achieved by the
TBP subunit, but rather by the TBP-associated factors
TAF250 or TAF150 (Chalkley and Verrijzer, 1999; Smale,
1997; Verrijzer et al., 1995; Wieczorek et al., 1998).
Our study of the initiator overlapping HPV-16 YY1-7436
led to contradictions with these three paradigms. YY1-
7436 in fact binds a YY1 factor such as AAV-P5, but is, in
contrast to AAV-P5, functionally independent of YY1, as
shown by the mutants YY1-7436m3 and m5, which re-
duce transcription without affecting YY1 binding. Second,
our bandshift experiments and nucleotide sequence in-
spection don’t suggest that YY1-7436 may bind TFII-I or
USF1. And third, the loss of function mutant m3, modeled
according to a TdT initiator mutant, suggests that YY1-
7436 resembles the TdT initiator, although it binds YY1 by
at least 1 order of magnitude more strongly than the TdT
initiator. In some respects, YY1-7436 resembles the pro-
moter of the human DNA polymerase  gene (Weis and
Reinberg, 1997). This TATA-less promoter has an initiator
that binds YY1 but functions independently of this factor.
A stable preinitiation complex could be established on
this promoter with recombinant TBP, TFIIB, TFIIF, and
RNA polymerase II, which was sufficient for transcription
initiation. In this study it has been proposed that RNA
polymerase II alone may have the capacity to recognize
initiators (Carcamo et al., 1991).
It is controversial whether there are multiple mecha-
nisms of activation of initiators. Alternatively, it has been
proposed that components of both RNA polymerase II
and TFIID (Carcamo et al., 1991) may recognize the
initiator, with other factors being regulatory factors that
act by binding near initiators (Kraus et al., 1996). One has
to consider that these observations are not necessarily
contradictory, but may reflect yet poorly understood lev-
els of the organization of transcription complexes. There
is evidence that YY1 can exist as a component of the
RNA polymerase II holoenzyme (Maldonado et al., 1996)
and that part of intranuclear YY1 is attached to the
nuclear matrix (Guo et al., 1995). This latter fact may be
relevant in the face of the observation that the 5 LCR of
HPV-16 is a MAR (Tan et al., 1998). Attachment of this
genomic segment to the nuclear matrix is, in part, medi-
ated by four strong binding sites for the CCAAT displace-
ment factor (CDP) (Stu¨nkel et al., 2000), which is a strong
repressor (Ai et al., 1999; Skalnik et al., 1991). The A-T-
rich sequence between the TATA box and the YY1-7436
initiator functions as a fifth, slightly weaker CDP binding
site, which is likely responsible for the negative regula-
tion of one of the tested clones (pGL3e58).
New promoters in the LCR and in the L1 gene of
HPV-16
We have reported here an examination of about 400 bp
of the genome of HPV-16 from the end of the L1 gene into
the enhancer for promoter activity in in vitro transcription
experiments. A single transcription start was detected. It
overlaps with a YY1 binding site, which is preceded by
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an A-T-rich sequence positioned 32 bp upstream of the
first transcribed nucleotide. The altered function of dele-
tions and the binding of TFIID/TBP suggest that it func-
tions as a TATA box. In transfected cells in vivo, the
initiator element and the TATA box support expression of
a reporter gene in a manner similar to the in vitro obser-
vations. Unfortunately, this promoter was not found to be
active by RT–PCR experiments under cell culture condi-
tions with nonchimeric HPV-16 molecules, such as in
20863 (W12) cells.
In consideration of the high activity of YY1-7436 in vitro
and in vivo transfection of cell cultures, the large number
of diverse constructs giving positive transcriptional re-
sponses, the conservation of this YY1 site in most genital
HPVs, and the position of similar promoters in the LCRs
of nongenital PVs argue that this promoter is likely to be
active at some point during the HPV-16 lifecycle. This
promoter may be inactive if it requires epithelial differ-
entiation signals not provided by the limited differentia-
tion conditions we could achieve. This promoter may be
modulated by factors associated with the nuclear matrix,
as YY1-7436 is positioned at the 3 border of a strong
MAR. One has to consider that the YY1 and E2 factors
themselves have affinity to the nuclear matrix (Guo et al.,
1995; Swindle et al., 1999) and may alter the topological
context of YY1-7436 depending on the physical state of
the HPV-16 DNA and on the availability of the factors. The
difficulties of numerous labs over many years in dissect-
ing late promoters of human or animal papillomaviruses
point to functional requirements for transcription initia-
tion that cannot yet be covered by the state of the art
technology.
While our RT–PCR experiments could not confirm tran-
scription starts at YY1-7436, they provided proof that LCR
sequences can become included into mRNAs. Surpris-
ingly, these data pointed to two promoters in unexpected
locations, namely, inside the L1 gene at the genomic
positions 6592 and 7057/8. The multiplicity of indepen-
dent clones derived from multiple independent RT reac-
tions and starting at these positions seems to preclude
an artifactual origin of these cDNAs.
The whole range of functions of the transcripts gener-
ated by the promoters at the positions 6592, 7057, and
7436 is hypothetical. While a contiguous transcript
through the center of the LCR would not include major
open reading frames, LCR transcripts can become
spliced to generate mRNAs encoding genes, as shown
by the transcripts reported above and as observed in
BPV-1 (Baker and Howley, 1987) and HPV-8 (Stubenrauch
et al., 1996). In HPV-16, the full-length E6 protein might be
translated more efficiently from LCR-containing mRNAs.
The first E6 AUG is at nt 83, upstream of the P97 tran-
scriptional start site, and the second in-frame AUG is at
nt 104, the eighth nucleotide of a P97-derived mRNA. It
had been speculated that the BPV-1 promoter p7185
(Baker and Howley, 1987; Vande Pol and Howley, 1990)
may generate an E1 mRNA (Stenlund et al., 1987). This
promoter is in a position in BPV-1 similar to that in
YY1-7436 in HPV-16 and is also regulated by a down-
stream E2 binding site. In HPV-31, a close relative of
HPV-16, a promoter originating at nucleotide position
7375 is found 88 bp upstream from an YY1-Inr corre-
sponding to that of HPV-16 (Ozbun and Meyers, 1999).
Multiple regulatory elements have been identified in
the LCR of genital HPVs, namely, elements to stabilize
and terminate late mRNAs, the epithelial-specific en-
hancer, a silencer, the replication origin, and the E6
promoter. Recent findings added to this the specific po-
sitioning of nucleosomes (Stu¨nkel and Bernard, 1999)
and regulatory influences by the nuclear matrix (Ai et al.,
1999; Tan et al., 1998; Stu¨nkel et al., 2000). Here we have
shown that HPV-16 contains, in addition to P97 and the
E7 internal promoter P670, at least three promoters, one
in the LCR and two in the L1 gene. Further research will
show whether these promoters have the potential to
generate late transcripts or whether they have additional,
unknown functions.
MATERIALS AND METHODS
Bacteria and mammalian cells
All cloning experiments were done in E. coli JM 109,
and all transfections in HeLa cells; 20863 cells are a high
copy HPV-16 episomal subclone of W12 cells modified in
P. Lambert’s lab and grown as published (Jeon et al.,
1995).
Oligonucleotides
All oligonucleotides (oligos) are listed in Table 1. For
bandshifts, approximately 200,000 cpm of radioactively
labeled oligos were used in each binding reaction with
nuclear extracts from HeLa cells (Dignam et al., 1983) in
a volume of 20 l with 5 mM spermidine (Sigma), 2 g of
bovine serum albumin (BSA), 50 mM KCl, 0.5% Igepal
(Sigma), 1 mM dithiothreitol (DTT), 1 mM phenylmethane-
sulfonate (PMSF), 0.75 mM MgCl2, and 10% glycerol.
Bandshifts for TATA box binding proteins were carried
out with E. coli expressed human TBP from Promega
(Cat. No. E 3081) in 20-l volumes with 5 mM spermidine,
2 g of BSA, 60 mM KCl, 0.1% Igepal, 1 mM DTT, 1 mM
PMSF, 6 mM MgCl2, 20 mM HEPES, pH 7.9, and 10%
glycerol. Expression of His-tagged YY1 in E. coli has
been described (O’Connor et al., 1996). For supershifts,
we used the anti-YY1 polyclonal antibody H-414 (Cat. No.
sc-1703 from Santa Cruz Biotechnology, Inc.) and an
anti-TBP binding antibody (Cat. No. 06-241 from Upstate
Biotechnology).
Plasmid constructs
pIII, containing the SV40 enhancer and the 21-bp re-
peat upstream of the insertion site for potential initiator
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sequences, used in in vitro transcription experiments,
was a gift of S. T. Smale (Zenzie-Gregory et al., 1992).
Oligonucleotides containing initiator sequences (Table 1)
were inserted into plasmids pSP72 (Promega) or pIII
between SacI and BamHI sites.
In order to study the function of the YY1 site at position
7436–7443 of HPV-16 (YY1-7436) and the E2 site at posi-
tion 7453–7464 (E2-7453) in vivo, we constructed lucif-
erase expression vectors with the basic (promoterless
and enhancerless) pGL3b vector and the promoterless
but SV40 enhancer containing pGL3e vector (Promega)
and inserted an oligonucleotide representing the HPV-16
sequence from 7456–7471 (including the EcoRI site at
position 7454) with artificial BglII and PstI sites or larger
HPV-16 segments expanded into the 5 direction, created
by polymerase chain reaction (PCR). The 5 ends were
placed at the genomic positions 6820, 7150, 7255, 7370,
and 7405. These segments were cloned blunt-ended in
the SrfI site of pCR-Script (Stratagene) and recloned into
pGL3b and pGL3e to create pGL3b651, pGL3b321,
pGL3b217, and pGL3b102 and pGL3e651, pGL3e321,
pGL3e217, pGL3e102, and pGL3e65, respectively, with
the HPV-16 EcoRI site as 3 border and restriction sites of
pCR-Script as 5 ends. The 1320-bp HPV DNA fragment
in the constructs pGL3b1320 and pGL3e1320 was ex-
cised as a BamHI–SphI fragment from a complete
HPV-16 genome, subcloned into BamHI–SphI cleaveded
pSP72, and inserted into pGL3b and pGL3e as a BamHI–
HindIII fragment. The 703-bp fragment containing the 5
MAR and enhancer fragment in pGL3b703 and
pGL3e703 was amplified by PCR, subcloned into pCR-
Script, and inserted into the respective vectors.
pGL3e102(E2m) was amplified from the pSP65-HPV16
genome with the primers CCAGAACATTTCTCTATCGAT-
AGGTA and GCAGCATGCAAAAGAATTCAATTGAA to mu-
tate the E2 DNA binding site from ACCGAATTCGGT to
AaaGAATTCaaT. Oligonucleotide fragments including
the upstream A-T-rich sequence were synthesized with
PstI and SacI ends and cloned into pG13b and pG13e to
create pG13b53 and pG1e53 (which have the A-T-rich
sequence, the YY1 site, and the E2 binding site) and
pG13b40 and pG13e40 (which have only the YY1 site and
the E2 binding site).
In vitro transcription
Plasmid DNA (300 ng to 1 g) was incubated in HeLa
nuclear extracts (100 g protein) in the presence of
nucleotide triphosphates (1 mM each), 20 units of ribo-
nuclease inhibitor (Promega), 16 l of HGED buffer (150
mM KCl, 70 mM HEPES, pH 7.9, 20 mM MgCl2, 1.5 mM
EDTA, 1.5 mM DTT, 20% glycerol) in a total volume of 50
l at 30°C for 1 h. To remove the template DNA, 50 l of
DNaseI mix (10 mM MgCl2, 1 unit of DNase I, 20 units of
ribonuclease inhibitor) was added and incubated at
37°C for another 15 min. The reaction products were
precipitated by ethanol, phenol–chloroform extracted,
washed with 80% ethanol, and dried. Transcripts gener-
ated from luciferase vectors were processed with the
oligo GGCCTTTCTTTATGTTTTT complementary to the
luciferase gene, transcripts from pSP72 and pIII with the
oligonucleotide GATTTAGGTGACATATAGA complemen-
tary to vector sequences, and transcripts from pGL3b703
with the primer GCATGGCAAGCAGGAAA, reverse com-
plimentary to HPV-16 enhancer sequences (position
7553–7537).
Primer extension
In vitro transcribed RNA was dissolved in 4 l of
hybridization buffer (1.25 M KCl, 50 mM Tris, pH 7.5, 5 mM
EDTA) together with 100,000 cpm of 32P-labeled primer,
and the volume adjusted to 20 l with 10 mM Tris, 1 mM
EDTA, pH 8. The primer–RNA mix was denatured at 95°C
for 3 min and annealed at 53°C for 30 min. After the
addition of 12 l of reverse transcription mix (250 mM
Tris–HCl, pH 8.3, 375 mM KCl, 15 mM MgCl2), 16 l of
dNTPs (2.5 mM each dATP, dCTP, dTTP, and dGTP), 6 l
of 0.1 mM DTT, and 1 l of Superscript II reverse tran-
scriptase (BRL) the reaction mix was incubated at 42°C
for 1 h and the reaction terminated by ethanol precipita-
tion. The precipitate was resuspended in 12 l of 10 mM
Tris, 1 mM EDTA, pH 8, and 3 l of 0.1 M NaOH. For
sizing the primer extension product, a DNA sequence
ladder was generated by cycle sequencing (30 cycles,
annealing at 53°C, extension at 72°C) with the same SP6
primer as in the primer extension. Plasmid DNA (500 ng)
with the initiator sequence, 0.5 pmol of radioactively
labeled primer, and 7.2 l of SequiTherm EXCEL II se-
quencing buffer (Epicentre Technologies, Madison, Wis-
consin) were distributed to four tubes containing 2 l of
the ddGTP, ddATP, ddTTP, and ddCTP termination mixes.
Transfection and luciferase assays
Hela cells were transfected with Superfect (Qiagen). A
day prior to transfection, 2 105 HeLa cells were seeded
per 60-mm dish; 5 to 20 g of plasmid DNA including the
plasmid pRLTK, added at 150th the concentration of the
pGL3e plasmid as internal control, was dissolved in 150
l of MEM, and 30 l of Superfect transfection reagent
was added and incubated at room temperature for 15
min. Concomitantly, the medium was aspirated and the
cells were washed with 4 ml of phosphate-buffered sa-
line (PBS); 1 ml of MEM (with serum and antibiotics) was
mixed with the DNA transfection mixture and added to
the cells. After incubation for 3 h at 37°C, the cells were
washed once with 4 ml of PBS, followed by addition of
fresh medium and incubation for 48 h prior to luciferase
assays. Luciferase activity was assayed with the Dual
Luciferase reporter assay (Promega). MEM was re-
moved, the cells were washed with PBS, 700 l of 1
passive lysis buffer (Promega) was dispensed onto each
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plate, the plates were rocked on an orbital shaker at
room temperature for 15 min, and the lysates transferred
to Eppendorf tubes. Firefly and Renilla luciferase activi-
ties were measured on a Turner TD-20/20 luminometer.
Cell lysates (20 l) were predispensed into luminometer
tubes and 100 l each of Luciferase Assay Reagent II
and Stop and Glo reagent were autoinjected sequen-
tially. The relative activities of the two luciferases were
recorded as the mean of four values.
RT–PCR assays of in vivo transcripts
The 20863 subclone of W12 cells containing episomal
HPV was grown as monolayers with or without cyclohex-
imide (25 g/ml) or trichostatin A at 33 nM. Total RNA
was isolated from 10-cm dishes using the RNAqueous kit
of Ambion Inc. RNA was treated with RQ1 DNase (Pro-
mega) in PCR buffer II and 5 mM MgCl2 for 15 min at
37°C followed by heating at 75°C for 10 min. Nested
RT–PCR was done using the GeneAMP RNA PCR kit
from PE Applied Biosystems. First strand cDNAs were
synthesized from the RNA using a random hexamer as
primer. The first round of PCR amplification was done
with either primers oCCB-181 (5 nt 7456) and oCCB-183
(5 nt 3597) or oCCB-189 (5 nt 7439) and oCCB-184 (5 nt
5931) for a total of 30 cycles with an annealing temper-
ature of 55°C and extension temperature of 72°C. The
second round of PCR amplification was done with either
primers oCCB-182 (5 nt 7475) and oCCB-187 (5 nt 3474)
or oCCB-182 (5 nt 7475) and oCCB-188 (5 nt 5711) using
the same cycling conditions. PCR primers are shown in
Table 1. PCR-amplified cDNAs were cloned into pCRII-
TOPO using the TOPO cloning method from Invitrogen.
cDNA inserts were sequenced using ABI PRISM BigDye
Terminator Cycle Sequencing reagents.
The 5 RACE was done using a template switching
technique (Chenchik et al., 1998). DNased RNA from
trichostatin A (TSA)-treated 20863 cells was reverse tran-
scribed with thermoscript (Invitrogen) at 55°C for 1 h.
The reverse transcriptase reactions were primed by ei-
ther random hexamers or a HPV-specific primer (oligo
68) and included a template switching primer (LP or oligo
59) (see Table 1B). Subsequently, the cDNAs were first
amplified by PCR with an HPV-specific antisense primer
(oligo 68) and a long universal sense primer containing
part of the LP sequence (oligo 62). All PCR amplifications
were carried out with platinum HiFi Taq polymerase in
the presence of 1 Extender (Stratagene). The products
from the first PCR reactions were reamplified with a short
universal primer (oligo 63) as forward primer and oligos
65, 66, and 67 as the reverse primers. The reactions were
analyzed on an agarose gel and a total of 30 bands were
excised and cloned into pCRII-TOPO vector (Invitrogen).
Plasmid DNAs of these clones were screened by PCR
with a pair of HPV-16-specific primers [oCCB-312 (5 nt
7455) and oCCB-313 (5 nt 7525)] to determine if the
particular clone contains HPV sequences. Positive
clones were sequenced to determine the exact DNA
sequence.
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